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Abstract: The presence of fat in the gastric environment can affect the pharmacokinetic 20 
behavior of drugs with mechanisms which have not been yet fully understood. The objective 21 
of the current study was to assess the drug partition to the lipid part of the fed gastric content 22 
under different emulsification conditions, using in vitro discriminating setups. The model drugs 23 
used in the study were selected on the basis of different physicochemical properties 24 
(lipophilicity, ionization, molecular weight and aqueous solubility) and different food effect 25 
observed in in vivo human studies. Fed State Simulated Gastric Fluid prepared with skimmed 26 
milk (FeSSGFsk) and anhydrous milk fat were used as surrogates for the aqueous and fat 27 
portions of the fed gastric environment respectively. An optimized biphasic model was 28 
developed so as to predict the differences in partition rate constants to fat, for model drugs of 29 
a wide range of the properties mentioned above. The experimental data and the use of statistical 30 
analysis revealed that molecular weight, molecular weight and log D pH 5 interaction and 31 
negative food effect act as negative factors to the rate constants of fat partition, while absence 32 
of food effect and logD pH 5 interaction with aqueous solubility affect the rate constants of 33 
partition to fat favorably.  34 
 35 
Keywords: Fed state, Physicochemical properties, Food effect, Drug partition, Partial least 36 





aq sol pH 5:calculated drug aqueous solubility at pH 5 (μg/mL), Ct:drug percentage partitioned to fat at time t, 40 
Cmax:maximum drug percentage partitioned to fat, DModY:distance to model; residuals of Y, FeSSGFsk:Fed state 41 
simulated gastric fluid prepared with skim milk, GF/D:glass microfiber, HGL:human gastric lipase, kpart:first-42 
order partition rate constant, log D pH 5:octanol/water distribution coefficient at pH 5, log P:octanol/water partition 43 
coefficient, MW:molecular weight, MWCO:molecular weight cut off, PLS:partial least squares, 44 
PRESS:predicted residual error sum of squares, Q2:crossvalidated coefficient of determination, , R2:coefficient 45 
of determination, RC:regenerated cellulose, Re:Raynold’s number, RN:Rhizopus niveus, rpm:rotations per min, 46 
SLS:sodium lauryl sulfate 47 
  48 
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1. Introduction 49 
The oral route is considered the most common route of drug administration, due to its 50 
convenience, lower cost of formulations developed and patient compliance. Drug solubility, 51 
dissolution and permeability are critical processes taking place in the gastrointestinal tract and 52 
determine the drug’s bioavailability. For most solid dosage forms (with the exception of 53 
orodispersing formulations), the stomach is the part of the GI tract where dissolution begins as 54 
the volumes and transit time in the oral cavity and oesophagus are insignificant. The stomach 55 
can be divided in three distinct parts: fundus, corpus and antrum; the fundus acts as a gastric 56 
reservoir, the antrum is the site where trituration and particle size reduction takes place, while 57 
the corpus connects these two parts (Koziolek et al., 2013). Food forms layers in the stomach, 58 
with fat floating on top of an aqueous layer and heavier particles sedimenting in the sinus 59 
(Schulze, 2006), while the aqueous layer contains small particles which are emptied from the 60 
stomach as the gastric emptying process takes place (Koziolek et al., 2013). The lipid part of 61 
the meal administered has a prominent role in a potential drug food effect through many 62 
possible mechanisms. Some common ones involve the increase of lymphatic transport of drugs 63 
(Hunt and Knox, 1968), the constriction of intestinal efflux transporters and the formation of 64 
intestinal mixed micelles (bile salt/phospholipids/cholesterol) as a result of exogenously 65 
administered lipids (Porter and Charman, 2001). Presence of fat in the stomach increases the 66 
gastric residence time of drugs thus allowing more time for drug dissolution. Moreover, the 67 
presence of lipid components in meals can modify the in vivo behaviour of certain molecules 68 
either promoting the formation of mixed micelles with bile salts or by drug solubilisation by 69 
fat. 70 
Thus, when developing in vitro predictive tests towards the evaluation of drug 71 
dissolution in the GI tract it is important to simulate the effect of the lipid part of the meal, 72 
incorporating it to the dissolution media used, with an aim to predict effectively possible food 73 
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effects on their pharmacokinetic behaviour. Since fat can improve the dissolution 74 
characteristics of poorly soluble drugs in the stomach, the knowledge of possible drug-lipid 75 
interactions is essential. Also, knowing the rate that the drug partitions to fat is equally 76 
important, as the meal remains in the gastric compartment for 1-4 hours (depending on the type 77 
of meal) (Read et al., 1986), with one part of the released drug being dispersed in the lipid 78 
phase and the rest solubilised or precipitated in the aqueous gastric phase. Of the total 79 
solubilised amount of drug, which includes both the free and partitioned drug, only the free 80 
fraction has the potential to be absorbed in the intestine (Porter et al., 2007). It is therefore 81 
important to determine the parameters which control drug-lipid interactions and evaluate 82 
possible dependence of drug physicochemical properties. Knowledge of the physicochemical 83 
parameters controlling this type of interactions can shed light towards the understanding of the 84 
mechanisms inducing positive or negative food effect after drug co-administration with high-85 
fat meals.  86 
Another factor which can affect drug dissolution and permeability in the gastrointestinal 87 
tract is the presence of lipolytic enzymes. Lipid digestion starts in the oral cavity with the help 88 
of lingual lipases and continues in the stomach from lingual and gastric lipases; while the major 89 
part of the lipolysis process takes part in the small intestine, where drug absorption takes place, 90 
primarily by the pancreatic lipase (Iqbal and Hussain, 2009). Gastric lipolysis was believed to 91 
account for 10-20% of the total lipolysis process in the GI tract (Carriere F. et al., 1993; 92 
Schonheyder and Volqvartz, 1946). More recent evidence though, showed that human gastric 93 
lipase (HGL) may be responsible for up to 40 % of the total lipolytic activity (Armand, 2007). 94 
Gastric lipase hydrolyses long and medium-chain to diglycerides, monoglycerides and fatty 95 
acids. These digestion products along with the shear forces developed in the stomach during 96 
digestion lead to fat emulsification, creating a coarse lipid emulsion (Thomas et al., 2012). 97 
Because of the limited role of HGL in the dissolution of conventional tablets, its use in gastric 98 
6 
 
dissolution media has been relatively limited. Its presence though may be important for lipid-99 
based drug delivery systems (Pedersen et al., 2013) and possibly in the prediction of drug 100 
dissolution behaviour after administration of lipid rich meals, as these ezymatic processes take 101 
place in both cases (lipids derived from food or lipid based formulations) (Rezhdo et al., 2016). 102 
In the fed state, gastric lipase contributes to a greater extent to the total lipolysis, due to higher 103 
HGL stimulation at higher pH values, with its activity measured more than 10 times higher at 104 
pH=5.4 than at pH=2.8 (Pedersen et al., 2013). 105 
In the fed stomach, un-digested fat forms a lipid layer floating on the top of the gastric 106 
content while emulsified fat particles move with the aqueous phase to the pyloric antrum; the 107 
aqueous content fills the distant antrum and moves towards the duodenum faster than fat and 108 
solid residues (Schulze, 2006). Because of the complex stratification of aqueous phase and un-109 
digested and emulsified fat in the fed stomach, it is important to assess the interactions formed 110 
between the drugs and each of the phases so as to explain certain lipid-induced changes in 111 
drugs’ pharmacokinetic parameters and also problems in the analysis of biorelevant media 112 
related to the presence of fat. 113 
The purpose of the current work was to study the role of the lipid part of a meal, 114 
simulated in a gastric fed state medium, in inducing changes of drug pharmacokinetic 115 
parameters. The percentage of drug partitioned to fat from the “aqueous” phase of the stomach 116 
under physiological conditions in the fed state was determined using three different 117 
experimental setups and 15 model compounds with a wide range of physicochemical properties 118 
were used. The effects of fat emulsification on drug partitioning to fat was also evaluated by 119 
performing experiments in the presence of surfactants. Statistical tools [partial least squares 120 
(PLS) regression analysis] were used to assess the impact of related drug physicochemical 121 
properties and drug food effect observed in vivo (changes in the drug’s pharmacokinetic 122 
behaviour after meal administration) on drug partition in fat. 123 
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2. Materials and Methods 124 
2.1. Materials 125 
Atorvastatin calcium salt trihydrate (≥ 98% (HPLC)), danazol (≥ 98%), furosemide (≥ 126 
98%), phenytoin (pharmaceutical secondary standard; traceable to USP and PhEur), 127 
itraconazole (≥ 98% (TLC)), propafenone hydrochloride (≥ 98% (HPLC)), indomethacin (≥ 128 
99%) and indoprofen (analytical standard) were purchased from Sigma- Aldrich, UK, while 129 
nifedipine (98.0-102.0% (on dried substance)) and ketoconazole (inclusive between 98.0%) 130 
from Fisher Scientific, UK. Griseofulvin (> 97%) and felodipine were purchased from Alfa 131 
Aesar, UK and ibuprofen (97-103%) was purchased from Fagron, UK. MK-C1 and MK-C4 132 
were provided by Merck & Co, US.  133 
Sodium acetate trihydrate, sodium chloride, hydrochloric acid (36.5-38%), glacial 134 
acetic acid (≥ 99%), sodium dodecyl sulphate (S/5200/53) and all phosphate salts were 135 
purchased from Fisher Scientific, UK. HPLC grade methanol, acetonitrile, trifluoroacetic acid 136 
(≥ 99.0%), diethylamine (≥ 99.5%), thriethylamine (≥ 99.5%) and formic acid were all 137 
purchased from Sigma- Aldrich, UK.  138 
Cronus 13 mm regenerated cellulose (RC) syringe filters 0.45 µm were purchased from 139 
LabHut Ltd, UK and 2.7 μm GF/D (glass fiber) filters from Fisher Scientific, UK. 140 
Lipase from Rhizopus niveus (Lipase RN, approximately 83 kDa, cat# 62310) and 141 
calcium chloride dehydrate (≥ 99.0%) were purchased from Sigma–Aldrich, UK. Sainsbury’s 142 
< 0.1% fat UHT milk and Sainsbury’s anhydrous milk fat were commercially purchased 143 
(Sainsbury’s, UK). Dialysis tubing cellulose membrane (MWCO 12000-14000, avg. flat width 144 
25 mm (1.0 in.)) was purchased from Sigma- Aldrich, UK. 145 
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2.2.  Instrumentation  146 
Partition experiments were run in triplicate at 37 °C, using 50 mL Corning® PP self-147 
standing centrifuge tubes, the USP 2 paddle apparatus (Agilent 708-DS Dissolution Apparatus) 148 
or 100 mL glass DURAN™ bottles (Fischer). All samples were analysed in an HPLC system 149 
consisting of an Agilent 1200 series binary pump (G1312A), an Agilent 1200 series DAD 150 
detector (G1315D), an Agilent 1200 series autosampler (G1329A), an Agilent 1200 series 151 
controller (G1316A) and Chemstation software (Agilent Technologies, Santa Clara, United 152 
States). A pH meter Mettler-Toledo AG (model SevenCompact pH/Ion S220, Schwerzenbach, 153 
Switzerland), a centrifuge Hereus Biofuge Primo R (Thermo Scientific, Hanau, Germany) and 154 
a vortex mixer Rotamixer (HTZ, Cheshire, UK) were used.  155 
2.3. Model drugs selection 156 
Assessment of the drug partition to fat was conducted for 15 drugs of a wide range of 157 
lipophilicity, ionisation, aqueous solubility, and in vivo food effect (Table 1). For drugs that 158 
were ionized in pH 5, the log D pH 5 was calculated based on the partition coefficient and the 159 
ionization constant of the studied drugs according to Equations 1 (weak acids) and 2 (weak 160 
bases) (Chiang and Hu, 2009): 161 
𝐥𝐨𝐠 𝑫𝒑𝑯 𝟓 = 𝐥𝐨𝐠 𝑷 − 𝐥𝐨𝐠(𝟏 +  𝟏𝟎
𝒑𝑯−𝒑𝑲𝒂)   for weak acids                      (Eq 1) 162 
𝐥𝐨𝐠 𝑫𝒑𝑯 𝟓 = 𝐥𝐨𝐠 𝑷 − 𝐥𝐨𝐠(𝟏 +  𝟏𝟎
𝒑𝑲𝒂−𝒑𝑯)  for weak bases                     (Eq 2) 163 
For neutral drugs or for weak acids/weak bases that were unionized in pH 5, log D pH 5 and log 164 
P were considered equal. Working drug concentrations were selected according to 165 
experimental drug aqueous solubility values as reported in the literature or calculated values 166 
where experimental values were not available (Advanced Chemistry Development 167 
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(ACD/Labs) Software v.11.02, Sci-finder), so as to avoid possible drug precipitation as the 168 
drug was initially dissolved in the “aqueous” (the part which does not contain fat, consisting 169 
of a mixture of skimmed milk and acetate buffer, FeSSGFsk) of the fed-state medium used in 170 
the study. Due to its extremely low solubility in water (< 0.1 μg/ mL), working concentration 171 
of MK-C4 was selected according to its solubility in the “aqueous” phase of the medium in a 172 
24 h period, performed using the shake-flask method (Wagner et al., 2012). In summary, an 173 
excess of drug was added to the solubility medium and left to equilibrate for 24 h at 37 °C 174 
under constant shaking. An aliquot of the saturated medium was initially filtered through a 175 
GF/D 2.7 μm filter and quantified after addition of ΑCN (2 parts in 1 part of medium), vortex 176 
(30 sec at full speed), centrifugation (15 min, 8000 rpm, 37 °C) and finally filtration through a 177 
regenerated cellulose filter. Drug was quantified in HPLC. 178 
2.4. Drug partition to fat studies 179 
A modified version of Fed State Simulated Gastric Fluid (FeSSGFsk; medium 180 
simulating the fed gastric composition early after drug administration (Dressman et al., 1990; 181 
Fotaki and Vertzoni, 2010) was selected in order to simulate the “aqueous” phase of the 182 
working fed state medium. FeSSGFsk was prepared according to Jantratid et al. (Jantratid et al., 183 
2008) by mixing skimmed milk and acetate buffer pH = 5 at a 1:1 volume ratio. For the 184 
preparation of 1 L of medium, 500 mL milk and 480 mL acetate buffer were mixed under 185 
constant stirring using a magnetic stirrer. pH was adjusted to 5 with 1 N HCl and the volume 186 
was adjusted to 1 L with acetate buffer. Anhydrous milk fat was selected as a surrogate of the 187 
lipid phase of FeSSGF. It is a cream or butter derivative, having water and proteins removed, 188 
and contains at least 99.8% milk fat (Rønholt et al., 2013). 189 
Three different setups were developed for the assessment of drug partition rate from 190 
the aqueous to the lipid part of the fed gastric medium (Table 2). The three setups used 50 mL 191 
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centrifuge tubes for diffusion through a dialysis membrane (setup I), the USP dissolution 192 
apparatus 2 (setup II) or 100 mL glass bottles for partition assessment of drugs in a smaller 193 
scale (setup III). For every drug, working solutions were prepared in FeSSGFsk and left under 194 
constant stirring at 37 °C for 60 min at concentrations equal to the drugs’ aqueous solubility 195 
values. Appropriate quantities of anhydrous milk fat, equivalent to the desired w/v percentage 196 
of the total volume of each setup (pre-heated at 37 °C) (Table 2) were weighed. Appropriate 197 
volume of the FeSSGFsk drug solution was placed in the receptor vessel of each setup. A 198 
working temperature of 37 °C was maintained by the means of a 37 °C incubator room, a 199 
thermostated jacket or a heating plate for setups I, II and III respectively. Drug partition rate to 200 
fat was described by measuring the % decrease in the donor concentration with time, with 201 
samples taken from the middle of the FeSSGFsk layer at defined time points for a period of 24 202 
or 48 hours. Experiments were performed in triplicate and % drug partition to fat was expressed 203 
as mean ± standard deviation. The exact quantities and volumes of lipid and aqueous parts, 204 
sampling time points and agitation conditions are stated in Table 2. The experimental setup 205 
suitability was evaluated with a pilot study of five drugs of different lipophilicity [propafenone 206 
hydrochloride, ketoconazole, nifedipine, danazol and atorvastatin calcium, (log D pH 5 = 0 -207 
4.20)]. 208 
The effect of fat percentage used was assessed in setup I (dialysis membrane setup), 209 
using nifedipine as the model drug. The quantity of fat placed in the membrane was equivalent 210 
to 5%, 8%, 15%, 20%, 25% w/v fat concentrations. 0.5 mL samples were collected from the 211 
donor compartment (30 mL of milk-based medium) at defined time-points (Table 2) and 212 
agitation was maintained by a 15 x 6 mm magnetic bar rotating at 300 rpm in a centrifuge tube 213 
with conical base and skirted bottom. Partition experiments using setup I were performed for 214 
the other four drugs of the pilot study using the 25% w/v fat concentration. The pore size of 215 
the membrane (MWCO 14000 Da), was multiple times higher than the molecular weight of the 216 
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model drug of the study (nifedipine-346.33 g/mol), and therefore allowed the process to be 217 
controlled by the affinity of drug for the receptor rather than the membrane. 218 
The effect of agitation speed was evaluated in setup II, using the dissolution apparatus 219 
paddle at 3 different speeds (150, 200 and 250 rpm) and danazol as the model drug and fat 220 
quantity equivalent to 25% w/v concentration of the total medium (Table 2). The volume of 221 
FeSSGFsk used was 500 mL. As emulsification between the two phases was observed during 222 
the experiments, agitation was stopped for 2 min for the two layers to separate before sampling. 223 
5 mL samples were withdrawn at defined time-points for a duration of 8 hours and volume was 224 
replaced with drug solution in FeSSGFsk. Partition experiments using setup II were performed 225 
for the other four drugs of the pilot study using 150 rpm agitation speed. Setup III, like setup 226 
II, was a biphasic setup without the presence of dialysis membrane but performed at a smaller 227 
scale (30 mL of FeSSGFsk). Agitation was provided by a 15 x 6 mm magnetic bar at 300 rpm. 228 
Agitation was paused for 2 min to allow for phase separation and 0.5 mL samples were 229 
collected from the drug donor compartment at defined time-points for a period of 8 hours.  230 
Once optimum parameters (fat percentage, medium volume, agitation means and speed) 231 
were selected, they were applied to all 15 drugs of the study. The experimental setup and the 232 
fat percentage added for the final setup developed were selected on the basis of providing 233 
adequate discrimination among drug partition profiles and reasonable times for complete 234 
profiles.   235 
Partition experiments in the presence of a surfactant were conducted using the partition 236 
setup III in order to assess the effect of emulsification conditions in the fed gastric environment 237 
on drug rate of partition. The partition rate constants were evaluated in the presence of an 238 
anionic surfactant (SLS) and also in the presence of a gastric lipase equivalent (RN lipase) 239 
dissolved in a CaCl2 solution added at a concentration yielding activity similar to the 240 
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physiological values (approximately 40 U/mL) (Armand, 2007; Diakidou et al., 2009a). 6 mL 241 
of a stock solution of SLS or RN lipase in acetate buffer pH 5 were added to 24 mL of drug 242 
solution in FeSSGFsk (same drug concentrations as in partition “control” experiments without 243 
the presence of SLS or enzyme). CaCl2 was added to a total 1.4 mM concentration. The 244 
concentration of the surfactant/enzyme stock solutions were selected so as to achieve a 1% w/v 245 
(for SLS) or 40 mg/mL (for lipase) concentration in the total volume of the system. FeSSGFsk 246 
and surfactant/lipase were left to mix for 5 min and the fat layer (10.3 g, Table 2) was added 247 
on top of the drug donor (FeSSGFsk and surfactant). Agitation was stopped for 2 min and after 248 
phase separation, 0.5 mL samples were taken from the drug donor at defined time-points for a 249 
period of 8 hours. Experiments were performed in triplicate and % drug partitioned was 250 
expressed as mean ± standard deviation. 251 
2.5. Sample treatment and drug quantification 252 
Drug quantification in FeSSGFsk: 2 parts of methanol were added to 1 part of FeSSGFsk 253 
immediately after its sampling and the mixture was vortexed (30 sec), centrifuged (8000 rpm, 254 
15 min, 4 °C), filtered through a 0.45 μm RC filter and analysed with HPLC. Drug was 255 
quantified against a set of calibration standards in FeSSGFsk treated as described above. 256 
Modifications of published chromatographic methods were used for drug quantification (Table 257 
3). 258 
2.6. Data analysis 259 
2.6.1. Data fitting 260 
In order to determine the rate constants of drug partition, partition data (drug % 261 
partitioned vs time) were fitted to a first-order model (Eq. 1) using GraphPad Prism v.7 262 
software (GraphPad, US). Goodness of fits was assessed on the basis of coefficient of 263 
determination and normality test.  264 
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Ft= Fmax  ∗ (1 − e
−kpartt)                                                                                                (Eq. 3) 265 
 Ft is the % drug partitioned to fat at time t, Fmax is the % maximum drug partitioned to 266 
fat (Fmax was not estimated by the model but the measured maximum % of drug partitioned 267 
into the fat was used) and kpart is the first-order partition rate constant.  268 
Drug partition rate constants were compared using a two-way analysis of variance 269 
(ANOVA) repeated measures (multiple measures of the same variable for all the studied levels 270 
under different experimental conditions), with Bonferroni’s post-hoc test, using GraphPad 271 
Prism v.7 software. The selected factors were: i. compound (Table 1) and ii. experimental 272 
setups (setup I, II, III). The effect of surfactant/lipase was evaluated using a two-way ANOVA 273 
for the comparison of partition rate constants with Bonferroni’s post-hoc test. The selected 274 
factors were: i. compound (Table 1) and ii. emulsification (surfactant, lipase). Statistical 275 
significance level was set at p < 0.05.  276 
2.6.2. Multivariate data analysis [Partial Least Squares (PLS) regression] 277 
The drug partition rate constants to fat were correlated to drug physicochemical 278 
properties [lipophilicity (log D pH 5), aqueous solubility at pH 5 (aq sol pH 5), molecular weight 279 
(MW)] and food effect [negative food effect (-), absence of food effect (0), positive food effect 280 
(+)] observed in in vivo human studies by partial least squares (PLS) regression using the 281 
XLSTAT software (Microsoft, US). The first order partition rate constant (kpart) was set as the 282 
response. As the impact of log D pH 5 on drug partition to fat may differ according to the drug 283 
physicochemical properties or the in vivo food effect, the combined effect of two variables on 284 
the response was assessed by including interaction terms of logD pH 5 with aqueous solubility 285 
at pH 5 (μg/mL), molecular weight (MW) and food effect in the model. The main advantage 286 
of PLS as a regression technique is the possibility to analyse data with independent variables 287 
which may be highly collinear (Wold et al., 2001). The parameters were selected on the basis 288 
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of the physicochemical aspects which control drug diffusion process between an aqueous and 289 
lipid layer. Assuming that the mechanism controlling the partition process is governed by the 290 
same basic principles as in lipid bylayers of biological membranes, drug partition is also 291 
dependent on drug diffusion coefficient and drug partition coefficient into the membrane 292 
barrier. Diffusion coefficient is dependent on size, shape and solvent-drug interaction. 293 
Therefore, even though log D is a good predictor for drug’s partition rate to fat, other 294 
parameters such as drug size and molecular weigh, which correlate to the diffusion coefficient, 295 
have to be considered. In vivo food effect is a complex phenomenon depending on several drug 296 
and/or gastrointestinal parameters and it was included in the model as an independent variable 297 
to investigate the role of drug partition to fat for the observed in vivo food effects. Interactions 298 
of log D pH 5 with the rest of the properties were included in the model with an aim to elucidate 299 
possible drug partition mechanisms for which drug lipophilicity alone cannot account for.  300 
The model quality was evaluated on the square of the coefficient of determination (R2) 301 
and goodness of prediction (Q2). R2 and Q2 values close to 1 refer to a model of good fit and 302 
prediction power respectively while a difference of R2 and Q2 lower than 0.2-0.3 between them 303 
is indicative of a successful model (Eriksson and Umetrics, 2008). A Q2 value > 0.5 was 304 
considered acceptable for good model predictability (Roy et al., 2015). Full cross-validation 305 
(leave-one-out procedure) was used to develop and evaluate the regression model. The 306 
optimum number of calibration factors (principal components) for each model was selected 307 
based on the model’s optimum predictability (Q2) and predicted residual error sum of squares 308 
(PRESS). Lower PRESS values indicate better prediction (Krishnan et al., 2011), with the 309 
number of latent variables where PRESS starts increasing indicating the number of variables 310 
which to be retained in the model (Abdi, 2010). The importance of each parameter was 311 
evaluated by its variable importance in projection (VIP) value. Values above 1.0 are considered 312 
to have a significant effect on the dependent parameter, whereas values < 0.7-0.8 are not of 313 
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statistical significance (Eriksson and Umetrics, 2008). The standardised coefficients of 314 
variance X (standardized coefficients calculated after mean-centering and scaling the data to 315 
unit variance (Eriksson et al., 2013)) indicate the relative positive/negative effect of their 316 
corresponding parameter on the first-order rate constant of drug partition to fat (response 317 
value). High absolute values of standardised coefficients for variance X denote a big positive 318 
or negative effect on response Y. Outliers in the PLS model were evaluated on the basis of 319 
DMoDY (distance to model; residuals of Y), which express distance from each point to the 320 
PLS model with respect to the responses with high values.  321 
3. Results and Discussion 322 
3.1. Effect of fat percentage on drug rate of partition 323 
The rate of drug partition to fat, was highly influenced by the percentage of fat present 324 
in the medium, as studied with partition setup I (dialysis membrane). A two-fold increase was 325 
observed in the rate constants of partition of nifedipine (drug with the highest fat affinity of the 326 
initial five compounds tested) when the fat content was increased from 5 to 25% w/v in the 327 
total medium (lipid and milk) volume (Figure 1a). The rate constant of nifedipine partition was 328 
doubled when fat concentration increased from 5 (0.05 h-1 rate constant) to 25% w/v (0.1 h-1 329 
rate constant) when partition data were fitted to a first-order equation, which can be attributed 330 
to the larger available area for diffusion when higher fat volumes are used, as described by 331 
Fick’s first law of diffusion (Erdélyi and Beke, 2003). For the three higher percentages used 332 
though (15, 20 and 25% w/v), the rate constants lied approximately between 0.08 and 0.1 h-1 333 
(Figures 1a, b). This signified a reduced effect of the fat percentage in partition rate constant 334 
for high fat medium content values. By increasing the amount of fat present in the receptor 335 
compartment, the percentage of total drug partitioned to fat in a period of 24 h also increased 336 
from 58% to 88% for 5% w/v and 25%w/v fat respectively.  337 
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3.2. Effect of hydrodynamics on drug rate of partition 338 
The evaluation of the effect of agitation in the drug partition setup II, using danazol as 339 
model drug for the study is presented in Figure 2. Using increased agitation rates (200 and 250 340 
rpm), almost 100% of the drug was diffused in the lipid layer during the first 30 min. Such high 341 
agitation would be difficult to use with model drugs which partition to fat faster or equally fast 342 
as danazol, as it would possibly provide inadequate discrimination among them; It can be seen 343 
that the profiles in the two high agitation rates were similar (Figure 2) and that the maximum 344 
portioned percentage is reached in the first 15 min. When the dissolution apparatus paddle was 345 
rotated at 150 rpm, a significantly slower partition profile was acquired with approximately 346 
60% of the drug partitioned from the FeSSGFsk to the lipid compartment in the first hour, and 347 
96% of the drug partitioned in the lipid layer in 8 h (Figure 2). Drug diffusion to the lipid layer 348 
is regulated by two static diffusion layers developed in the two sides of the oil-“aqueous” 349 
interface with drug diffused through them from the aqueous to the lipid part (Mudie et al., 350 
2012). Assuming that the width of the two layers remains constant though time, the parameters 351 
affecting the partition behaviour are: liquid viscosity, vessel dimensions, type of agitator and 352 
agitation speed, with the latter being the only parameter changing in the current study, 353 
justifying the differences observed in the rate constants of drug partition (Mudie et al., 2012). 354 
3.3. Effect of experimental setup on drug rate of partition 355 
The 25% w/v fat percentage was the percentage selected for the evaluation of the 356 
different proposed setups for the discrimination of partition rate constants to fat between drugs, 357 
even though the % w/v fat in the FDA high-fat standard breakfast (Klein et al., 2004) or in fed 358 
gastric media used in vitro such as milk, FeSSGF (Fed State Simulated Gastric Fluid) (Jantratid 359 
et al., 2008) and Ensure® Plus (Franek et al., 2014) is lower (≈ 1.8-14% w/v). The high fat 360 
percentage provided the highest partition rate constant compared to the other fat concentrations 361 
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studied (Figure 1b), making the discrimination among the various drugs easier, as observed 362 
from the results of the pilot study in setup I.  363 
The five model drugs which were evaluated in the pilot study, using all three setups 364 
(Figure 3), all provided significantly different partition rate constants to fat (p < 0.05, two-way 365 
ANOVA) (Figure 4). In all setups, nifedipine showed the highest affinity for the lipid phase, 366 
while the whole amount of propafenone hydrochloride practically remained in the “aqueous” 367 
part throughout the duration of the study, possibly because of the latter’s low distribution 368 
constant (log D = 0) in the working pH.  369 
Using setup I, the whole process was extremely slow for the four of the five model 370 
compounds of the study, with the exception of nifedipine, with the amount of drug partitioned 371 
to the fat being < 20% in the first 8 h (Figure 3a). A plateau of the percentage partitioned could 372 
not be reached even after 48 h for all the model compounds, while phase separation of the milk-373 
based medium was observed after 2 days. The decreased rate constant of the drugs’ partition 374 
process can be attributed to the increased viscosity of the receptor (fat), which slowed down 375 
drug diffusion (Xu et al., 2012). The slow reaction rate constants (especially for compounds 376 
other than nifedipine) may be considered a disadvantage for the current setup. Moreover, using 377 
the above setup, no significant differences were observed (p < 0.05) among the rate constants 378 
of drug partition for the five model drugs used (Figure 4). 379 
Setup II resulted in the highest partition rate constants for the five drugs initially studied 380 
(Figure 3b). Discrimination among the partition rate constants of the model compounds to fat 381 
was observed (Figure 4). The drugs’ partition rate constants to fat ranged between 0.39 h-1 (for 382 
ketoconazole) and 13.58 h-1 (for nifedipine). The volumes used were similar to the fed gastric 383 
volume in vivo (Koziolek et al., 2014; Kwiatek et al., 2009), but the hydrodynamics of this set 384 
up are different from the hydrodynamics observed in the fed stomach, as portrayed by the 385 
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differences in Reynold’s number between the fed stomach and the vessels in dissolution 386 
studies. USP 2 dissolution apparatus, at speeds between 50 and 100 rpm, results in Re numbers 387 
between 5000 and 10000 (Mudie et al., 2010), while the equivalent values of the fed stomach 388 
in vivo are between 0.01 and 30 (Abrahamsson et al., 2005). 389 
Since the stationary level of the fluid is multiple times higher in the USP 2 dissolution 390 
apparatus, and is the factor with the biggest effect, (as the medium is the same in both cases), 391 
it would be reasonable to assume that Re values in the setup III model are probably closer to 392 
the values resulting from the hydrodynamics developed in the fed stomach in vivo. The partition 393 
rate constants to the fat for the drugs studied in setup III were: 0.22 (± 0.06), 0.20 (± 0.07), 394 
0.33 (± 0.07) and 1.64 (± 0.04) h-1 for ketoconazole, atorvastatin calcium, danazol and 395 
nifedipine respectively, while propafenone’s transfer to fat was insignificant (Figure 3c). 396 
Adequate descrimination between the drugs’ partition profiles, lower medium volume and drug 397 
consumption and reproducible results were obtained with this experimental set up (Figure 4). 398 
Therefore, it was selected for the investigation of partition to fat for the rest of the drugs. Setup 399 
III partition data were successfully fitted to the first-order equation model, with R2 values of 400 
0.90-1.00 and residuals randomly scattered (Figure 3c, Table 4). The highest partition rate 401 
constants were observed for nifedipine (1.64 h-1) and ibuprofen (1.17 h-1), followed by 402 
indomethacin (0.70 h-1) and griseofulvin (0.63 h-1) (Table 4). It can be observed that the four 403 
drugs partitioned to the lipid part the fastest are of intermediate lipophilicity (log D pH 5 = 2.20-404 
3.62). Our hypothesis is that the increased partition rate constants of drugs of moderate 405 
lipophilicity is attributed to a combination of adequate drug affinity to fat and also high drug 406 
amount available in soluble form in the aqueous donor compartment. The above hypothesis is 407 
based on the principles which govern the incorporation of lipophilic drugs in previously formed 408 
liposomes, where despite drug increased drug lipophilicity, its rate of incorporation is 409 
controlled by the amount of drug available in the aqueous donor phase, with drug dissolution 410 
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in it being the rate limiting step, often leading to very slow rates if not adequate (Cannon et al., 411 
2008). The decreased drug solubility in the medium may explain the absence of drug partition 412 
to fat for MK-C4, the most lipophilic drug in the current study (Figure 3c, Table 4). The rate 413 
constants of partition of the other four drugs of high lipophilicity (drug represented with red 414 
markers in partition profiles, Figure 3c) ranged from approximately 0.2 to 0.4 h-1. The absence 415 
of partition (rate constant  0 h-1) for propafenone hydrochloride and furosemide (Figure 3, 416 
Table 4) was attributed to decreased drug lipophilicity (log D < 1.5) in the working pH. The 417 
percentage of the total drug partitioned to the fat in the duration of the study (8 h) was > 78% 418 
for 9 of the 15 model drugs (Figure 3c, Table 4). The lower F8h percentages were observed for 419 
drugs of low lipophilicity (propafenone hydrochloride, furosemide, phenytoin, indoprofen) and 420 
can be attributed to their low affinity for fat. Drug transfer process between these two 421 
immiscible layers is governed by three steps; firstly, its diffusion towards the interface, its de- 422 
and re-solvation at the interface and, lastly, a new diffusion step from the interface to the lipid 423 
layer (Grassi et al., 2002). Therefore, the insignificant partition of the drug with the highest log 424 
D, MK-C4, could possibly be explained by the drug’s limited ability to dissolve in the 425 
“aqueous”/organic interface.  426 
3.4. Effect of drug physicochemical properties on drug rate of partition 427 
The relationship between drug partition rate constants and drug lipophilicity (log D pH 428 
5) follows a bell-shaped distribution around a maximum of log D = 2-4 (Figure 5). Several 429 
moderately lipophilic drugs (nifedipine, ibuprofen) of the study partitioned to fat faster than 430 
others of higher lipophilicity (felodipine, itraconazole) indicating that lipophilicity is not the 431 
sole parameter affecting the process.  432 
Partition data (rate constants) showed that molecules of molecular weight higher than 433 
500 g/mol partition to the lipid layer of the gastric medium at a slow rate relatively to the other 434 
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model drugs, despite their high lipophilicity (e.g. atorvastatin calcium, ketoconazole, 435 
itraconazole, MK-C4) (Figure 5). Ionisation is also a parameter affecting drug partition into 436 
the lipid phase; for ionisable compounds, their un-ionised form is more easily partitioned to 437 
the lipid membranes (Fan and de Lannoy, 2014). It can be assumed that having the model drug 438 
in its un-ionised from in the aqueous donor (FeSSGFsk) would facilitate its partition to the lipid 439 
layer. Out of the 15 model drugs of the study, the ones being ionised at a percentage higher 440 
than 95% in the working pH (according to their pKa values, Table 2) demonstrated the lowest 441 
partition rate constants, regardless of their lipophilicity (Tables 2, 4, Figure 5).  442 
The impact of aqueous solubility at the working pH, lipophilicity and MW and in vivo 443 
food effect on drug partition behaviour was evaluated using partial least squares regression 444 
analysis. The initial PLS analysis for the rate constant of partition (1 principal component) 445 
which included all model drugs of the study, gave a model of moderate predictive power (Q2 = 446 
0.33) and fit (R2 = 0.43) to the experimental values. Of the 15 drugs, nifedipine behaved as an 447 
outlier, with partition rate constants significantly higher than the model predicted (DMoDY 448 
values for nifedipine were 2.2-2.4 times higher than the critical value given by the software for 449 
the specific PLS model). Nifedipine’s affinity to fat can be seen in the lipid percentage-450 
dependent solubility of the drug in fed gastric media in vitro, as derived from its values in fed 451 
gastric media of 3.5, 1.75 and 0.875% w/v fat, (approximately 12x, 7x and 4x solubility for 452 
early, middle and late FeSSGF compared to aqueous buffers of the same pH and buffer 453 
capacity) (Andreas et al., 2016). Fast partition to fat could be one of the reasons of nifedipine 454 
being a drug which exhibits positive food effect when administered with high fat meals (Schug 455 
et al., 2002) with more drug being solubilised by the lipid content of the gastric environment 456 
after meal administration. Reconstructing the model without including nifedipine gave a model 457 
defined by 2 principal components of Q2 and R2 values of 0.55 and 0.66 respectively, with 458 
acceptable predictive power. 459 
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Molecular weight (VIP = 1.0) was defined as negative predictor for drug partition to fat 460 
(negative standardised coefficient) (Figure 6). Molecular weight > 500 is considered a limiting 461 
negative factor for drug permeation to lipid membranes through passive diffusion (Banks, 462 
2009; Lipinski et al., 2001). As observed by the negative standardised coefficient of the log D 463 
pH 5*MW interaction (VIP = 1.3), the effect of lipophilicity is different for drugs of different 464 
molecular weights. Looking at the drug partition rate constants (Table 4), it can be 465 
demonstrated that even extremely lipophilic drugs which do not have a reasonably low 466 
molecular weight, cross the lipid-aqueous interface barrier at a low rate (Figure 5). Positive log 467 
D pH 5*aq sol pH 5 interaction (VIP = 1.1) indicates that the effect of drug lipophilicity on the 468 
rate constant of partition to fat differs according to drug aqueous solubility. Positive food effect 469 
is generally associated with drug lipophilicity though lipid emulsification of lipophilic drugs 470 
in the stomach (Porter et al., 2008) and increase in drug luminal solubility (Porter and Charman, 471 
2001). The model build failed to demonstrate any correlation between positive food effect and 472 
drug-fat interaction, as the statistically non-significant negative coefficient indicates (Figure 473 
6). On the contrary, the model demonstrated a negative correlation (Figure 6) between partition 474 
rate constants to fat with negative food effect in vivo (VIP = 1.2). Drugs of which 475 
pharmacokinetic behaviour does not change as a result of meal administration (no food effect), 476 
appear to partition to fat significantly faster than the rest (positive standardised coefficient, VIP 477 
= 1.7), which is another indication that partition to fat alone cannot be used as a sole predictor 478 
for changes in drug pharmacokinetic parameters after administration of high-fat meals. 479 
3.5. Effect of emulsification conditions on drug rate of partition 480 
When 1% w/v of SLS was added to the drug donor, in order to simulate an extreme 481 
version of the emulsification of the fat taking place in the fed gastric environment, enhancement 482 
of the drug partition rate constants to fat was observed for 9/15 drugs following first-order 483 
kinetics both in presence and absence of surfactant. The increase in the rate constant of the 484 
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partition process ranged from 11.4% (indoprofen) to 335.8% (felodipine), while a slight 485 
decrease compared to the partition rate constant in the absence of SLS was reported for three 486 
of the drugs (4.7, 10.0 and 29.5% decrease in partition rate constants for ibuprofen, griseofulvin 487 
and itraconazole respectively) (Figure 7a, Table 4). The presence of SLS in the drug donor 488 
compartment had a statistically significant effect on the drug partition rate constants, compared 489 
to the profiles in the absence of surfactant (p < 0.05). The difference in partition rate constants 490 
to fat is a result of two conflicting phenomena; i. higher drug affinity for the donor in the 491 
presence of surfactant and ii. bigger available receptor surface area for partition compared to 492 
the control experiment. The addition of SLS under constant stirring breaks the fat into smaller 493 
droplets which increases their surface area (Gunstone, 2007). In the fed stomach, where fat 494 
emulsification takes place, as a result of the agitation conditions and the presence of lipid 495 
digestion products, the diameter of fat droplets is significantly reduced with the emulsion 496 
surface area demonstrating a three-fold increase (Schulze, 2006), which justifies the increase 497 
in partition rate constants in this study, after the addition of SLS. The presence of surfactants 498 
(emulsifiers, proteins or lipolysis products) in the lipid-water interface can reduce the surface 499 
tension increasing the diffusion kinetics by increasing the drug interfacial permeability, 500 
compared to the large surface tension of the non-emulsified lipid-water interface, where 501 
partition phenomena are slow (Rezhdo et al., 2016). 502 
The partition process is drug dependent with significant difference observed among 503 
different drugs (p < 0.05). Higher rate constants of partition to fat were observed for moderately 504 
lipophilic drugs (logD pH 5 values 2-4) and lower rate constants for drugs of extreme low or 505 
high lipophilicity (Figure 8a). A bell-shaped curve is observed for the correlation of partition 506 
rate constants with log D pH 5 (Figure 8a). 507 
The PLS analysis for the rate constants of partition (1 principal component) which 508 
included all model drugs of the study except for nifedipine, gave a model of good predictive 509 
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power (Q2 = 0.41) and fit (R2 = 0.51) to the experimental values. Absence of food effect (VIP 510 
= 1.9) and the interaction of log D pH 5 with negative food effect (VIP = 1.1) were defined as 511 
positive predictors for drug partition to fat (positive standardised coefficients) (Figure 9). Faster 512 
partition rate constants to fat both in presence and absence of the surfactant, in drugs of similar 513 
bioavailability in fasted and fed conditions, is another indication that drug rate partition to fat 514 
is not directly associated with in vivo positive food effect. On the contrary, a negative 515 
correlation between positive in vivo food effect can be observed from the negative standardised 516 
coefficient (VIP = 1.4) in the model (Figure 9). In the fed stomach, during gastric emptying, 517 
aqueous content is transferred to the duodenum significantly faster than fat, which is held by 518 
the angular notch (Schulze, 2006). Therefore, if the drug is adequately soluble in the watery 519 
portion of the gastric content, aided by the natural surfactants present (a role played by the 520 
surfactant in the developed in vitro partition setup), slower partition to the lipid layer would 521 
mean increased drug quantity available for transfer to the intestinal environment. A slower 522 
partition to fat therefore, provided that the drug is adequately soluble and does not precipitate 523 
in the aqueous part of the stomach, may be associated with positive food effect. Negative effect 524 
of drug aqueous solubility (VIP = 1.1) is attributed to the high affinity of highly soluble drugs 525 
for the “aqueous” compartment. The impact of drug lipophilicity on the rate constants of 526 
partition to fat differs according to drug molecular weight and drug aqueous solubility, as 527 
indicated by the significance of the log D pH 5 andMW (VIP = 1.1) and log D pH 5 andaq sol pH 5 528 
(VIP = 1.1) interactions. 529 
In the presence of the lipase, the differences in partition behaviour among drugs of different 530 
lipophilicity were subtler (Figure 8b) than in the presence of SLS. Rate constants of partition 531 
ranged from 0.207 h-1 (atorvastatin calcium) to 1.354 h-1 (nifedipine) (Table 4). Although 532 
partition rate constants for all drugs were equally high or slightly higher than in the absence of 533 
the enzyme (Table 4, Figure 3c, 7b), the differences were not statistically significant, which 534 
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implied that the partition rate constants to fat were not affected by the presence of the lypolytic 535 
enzyme. MK-C1 and nifedipine demonstrated slightly slower rate constants than in the absence 536 
of lipase by 1.11 and 1.21 times respectively. Similarly, to the other two conditions (absence 537 
of surfactant/enzyme and presence of SLS), drugs of intermediate lipophilicity (blue markers 538 
in Figure 7b) partition to fat faster and to a higher percentage than extremely lipophilic (red 539 
markers) and hydrophilic (white markers) drugs. Except for the three most hydrophilic drugs 540 
(propafenone hydrochloride, furosemide, indoprofen) and the extremely lipophilic MK-C4, a 541 
percentage higher than 80% of all drugs partitioned to the fat layer in a period of 8 hours except 542 
for itraconazole (Figure 7b, Table 4). Interestingly, in the presence of lipase, itraconazole 543 
started diffusing to fat only after 3 hours and only 32.4% of the initial drug concentration 544 
partitioned to fat in 8 hours.   545 
The bell-shaped distribution around log D values of 2-4, (Figure 8b) indicates that in 546 
the presence of lipase, drug partition behaviour is not only governed by the drug lipophilicity, 547 
but it can be also controlled by other physicochemical parameters, an effect confirmed by the 548 
multivariate analysis of data. Looking at the partition rate constants against MW and un-ionised 549 
drug fraction plots (Figure 8b), the rate of partition seems to be affected by MW and drug 550 
ionisation to a smaller extent.  551 
The PLS analysis for the rate constants of partition (1 principal component) which 552 
included all model drugs of the study except for nifedipine, gave a model of good predictive 553 
power (Q2 = 0.55) and fit (R2 = 0.65) to the experimental values. The main variables with a 554 
negative effect on drug rate constants of partition were drug MW (VIP = 1.2), logD pH 5*MW 555 
interaction (VIP = 1.8) and drug aqueous solubility (VIP = 1.1) (Figure 10). The negative effect 556 
of the former is attributed to the negative correlation of molecular weight on drug diffusion 557 
coefficient (Valencia and González, 2011). The effect of logD pH 5 differs with MW, as the 558 
negative log D pH 5*MW interaction indicates. Drug aqueous solubility is negatively correlated 559 
25 
 
with drug partition rate constant due to higher affinity for water-soluble compounds for the 560 
donor compartment. The positive standardised coefficient of logD pH 5*aq sol pH 5 (VIP = 1.3) 561 
indicates that a possible positive correlation of drug partition rate constant with its lipophilicity 562 
is dependent on drug aqueous solubility. This positive coefficient could be an indication that 563 
lipophilicity is a parameter favourably affecting the partition process, provided that the drug is 564 
adequately soluble in the donor compartment. The absence of in vivo food effect was a 565 
significant variable in the model (positive standardized coefficient, VIP = 1.3), indicating that 566 
the drug rate partition constant to fat is not directly associated with the impact of meal presence 567 
on drug bioavailability. 568 
4. Conclusions 569 
Drug interaction with fat has been closely related to possible in vivo food effect after 570 
drug administration with meals of high lipid content. The current study strove to depict the 571 
drug partition process to the lipid phase of the fed stomach content by developing an in vitro 572 
discriminating method, able to assess the differences in rate constants of drug partition to fat 573 
using model drugs of a wide range of lipophilicity, ionisation and food effect. The in vitro setup 574 
developed provided discrimination of drug partition rate constants. The study revealed that 575 
increasing the percentage of fat and the lipid and aqueous compartment volumes while reducing 576 
the agitation conditions resulted in significantly enhanced the partition rate constants. Drugs of 577 
moderate lipophilicity partitioned to fat faster compared to low or high lipophilic drugs. The 578 
study revealed the importance of drug physicochemical properties, as the rate constants of drug 579 
partitioned to fat depended also on drug MW and drug aqueous solubility. The complex role 580 
of drug partition to fat was depicted by the significance of several interaction terms using 581 
multivariate data analysis. Faster drug partitioning to fat can be anticipated when surfactants 582 
are included in the setup due to fat emulsification. The current investigation revealed a 583 
correlation between drugs demonstrating negative food effect and slow partition to fat. 584 
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However, it is important to highlight that food effect on bioavailability depends on a number 585 
of complex mechanisms and cannot be predicted solely based on the elucidation of lipid-drug 586 
interactions in the fed stomach. Moreover, conclusions on drug partition rate constants must 587 
not only be based on API properties but the effect of drug formulation must also be considered. 588 
Further studies, investigating also the drug “release” from the lipid part of the gastric fed 589 
content to the intestinal environment combining the partition principles of developed setup 590 
with simulated intestinal media could potentially shed light towards better understanding of 591 
food effect mechanisms. 592 
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Table 1: Physicochemical properties and working concentrations of model drugs; “+” indicates positive food effect, “-“negative food effect and 856 
“n.e.” no food effect. 857 
Drug Food effect log P log D pH 5a 
pKa (Law et 
al., 2014) 
Un-ionised 










2.29 (Granero et 
al., 2010) 




+ (Aoyagi et 
al., 1982) 
2.50 (Fagerberg 
et al., 2015) 
2.50 - 100 
353 
8.6 (Wishart et al., 2006)  
Phenytoin 
+ (Hamaguchi 
et al., 1993) 
2.47 (Fleisher et 
al., 1990) 
2.47 9.47 (acidic) 100 
253 
27 (Mithani et al., 1996) 
Ibuprofen 
n.e (Pargal et 
al., 1996) 
3.97 (Potthast et 
al., 2005) 





et al., 1977) 
2.50 (Fagerberg 
et al., 2015) 
1.21 3.74 (acidic) 5 
281 
128 (Wishart et al., 2006) 
Nifedipine 
+ (Schug et al., 
2002) 
2.20 (Gajendran 
et al., 2015) 
2.20 13.00 (basic) 100 




+ (Axelson et 
al., 1987) 
3.39 (Cramer et 
al., 2007) 




- (Männistö et 
al., 1982) 
4.40 (Diakidou 
et al., 2009b) 
2.64 6.75 (basic) 2 
531 
2.7b 
MK-C1c n.e 4.00 4.00 6.50 (acidic) 100 777 3c 
Danazol 
+ (Charman et 
al., 1993) 
4.20 (Fagerberg 
et al., 2010)  
4.20 - 100 
337 1 (Dressman and Reppas, 







et al., 1995) 
4.82 (Rageh et 
al., 2017) 




n.e (Aoyagi et 
al., 1990) 
3.50 (Fagerberg 
et al., 2015) 
2.27 3.80 (acidic) 6 
358 






et al., 2015) 
4.80 - 100 
384 
1.1 (Fagerberg et al., 
2010) 
Itraconazole 
+ (Barone et 
al., 1993) 
6.20 (Maincent 
et al., 2017) 
5.60 3.70 (basic) 23 
706 
3.7c 
MK-C4c + 8.81 8.81 - 100 638 3.2d 
a Calculated based on equations 1 and 2 858 
b Working drug concentrations based on calculated drug aqueous solubility values (Advanced Chemistry Development (ACD/Labs) Software v.11.02, Sci-finder) 859 
c Physicochemical properties and food effect data provided by Merck 860 
d Solubility study (24 h) performed in FeSSGFsk  861 
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Table 2: Experimental conditions of drug partition to fat setups. 862 





FeSSGFsk volume (donor) 
(mL) 
30 500 30 
Anhydrous milk fat nominal 
quantity (g) 
10.3 172 10.3 
Anhydrous milk fat nominal 
concentration (% w/v) 
5-25 25 25 




Glass bottle (100 
mL) 
Sampling point Middle of FeSSGFsk layer 
Sample volume (mL) 0.5 5 0.5 
Agitation speed (rpm) 300 150 300 
Membrane length (cm) 8 cm - - 
Membrane type Cellulose membrane 
avg. flat width 25 
mm (1.0 in.), 
MWCO 14000 
- - 
Sampling time points (h) 0.5, 1, 1.5, 2, 2.5, 3, 
4, 6, 8, 24, 48* 
0.17, 0.33, 0.5, 1, 
1.5, 2, 3, 4, 6, 8 
0.5, 1, 1.5, 2, 2.5, 
3, 4, 6, 8 
Temperature (°C) 37 
*24 h sampling time for nifedipine, 48h sampling time for all other drugs 863 






Magnetic stirring bar 
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Table 3: HPLC methods (or modification of published methods) used for the quantification of the model compounds 864 





Inj. Vol. (μl) λ (nm) 
MK-C4* 
Phenomenex Onyx monolithic 
C18, 300Å, 250 x 4.6 mm, 5 μm 
ΑCN:H2O 70:30 3.5 40 100 220 
Itraconazole (Vertzoni et al., 
2006a) 
Thermo Hypersil BDS C18, 
300Å, 250 x 4.6 mm, 5 μm 
MeOH:H2O 80:20 1 35 100 260 
Felodipine (Diakidou et al., 
2009a) 
Waters XBridge Shield RP18, 
130Å, 150 x 4.6, 3.5 μm 
ΑCN:H2O 70:30 1 25 100 238 
Indomethacin (Maharaj et al., 
2016) 
Waters XBridge Shield RP18, 
130Å, 150 x 4.6, 3.5 μm 
MeOH:Phosphoric acid 1.67% 
v/v 
1 23 50 270 
Atorvastatin calcium 
(Elshanawane et al., 2014) 
Thermo Hypersil BDS C18, 
300Å, 250 x 4.6 mm, 5 μm 
ΑCN:Phosphate buffer  
0.025 M 
(pH 6) 40:60 
1.5 30 100 246 
Danazol (Zhang et al., 2008) 
Thermo Hypersil BDS C18, 
300Å, 250 x 4.6 mm, 5 μm 
MeOH:H2O 75:25 1 25 100 285 
MK-C1* 
Waters Symmetry Shield C18, 
100Å, 50 x 4.6 mm, 5 μm 
ΑCN:Phosphate buffer 0.025 
M (pH=2.5) Gradient (0-2 min 
65:35/ 2-2.01 min 90:10/ 2.01-
3 min 90:10/ 3-3.01 min 65:35 
3 40 100 214 
Ketoconazole (Diakidou et al., 
2009b) 
Thermo Hypersil BDS C18, 
300Å, 250 x 4.6 mm, 5 μm 
MeOH:H2O:DEA 75:25:0.1 1 25 100 260 
Propafenone hydrochloride 
(Borijihan et al., 2014) 
Agilent Eclipse XDB C18, 
120Å, 250 x 4.6 mm, 5 μm 
MeOH:ΑCN: 
TEA:H2O 




25 20 248 
Nifedipine (Vertzoni et al., 
2006b) 
Thermo Hypersil BDS C18, 
300Å, 250 x 4.6 mm, 5 μm 
MeOH:H2O 
60:40 
1 20 50 238 
Indoprofen (Locatelli et al., 
2014) 
Waters XBridge Shield RP18, 
130Å, 150 x 4.6, 3.5 μm 
ΑCN:Formic acid 0.1% v/v 
40:60 
1 40 50 280 
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Ibuprofen (Tan et al., 2014)  
Agilent Eclipse XDB C18, 
120Å, 150 x 4.6 mm, 5 μm 
MeOH:Acetic acid 0.2% v/v 
60:40 
1 25 100 233 
Phenytoin (Maharaj et al., 
2016) 
Agilent Zorbax SB-C18, 
150 × 4.6 mm, 3.5 μm 
ACN:H2O 80:20 1 20 10 210 
Griseofulvin (Maharaj et al., 
2016) 
Waters XBridge Shield RP18, 
130Å, 150 x 4.6, 3.5 μm 
MeOH:H2O 65:35 0.8 20 50 292 
Furosemide (Sora et al., 2010) 
Thermo Hypersil BDS C18, 
300Å, 250 x 4.6 mm, 5 μm 
MeOH:Formic acid 0.1% v/v 
60:40 
0.8 25 20 233 
*HPLC methods provided by Merck 865 
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Table 4 Drug first-order partition rate constants to fat (kpart) and % drug partitioned to fat at 8h (F8h) in the absence and presence of SLS and lipase. 866 
Drug No emulsifier SLS Lipase 
 kpart (h-1) F8h (%) kpart (h-1) F8h (%) kpart (h-1) F8h (%) 
propafenone hydrochloride 0 (0)* - 0 (0) - 0 (0)* - 
furosemide 0 (0)* - 0 (0) - 0 (0)* - 
indoprofen 0.429 (0.049) 19.4 (7.1) 0.477 (0.087) 25.0 (0.6) N/A 30.8 (1.9) 
ketoconazole 0.223 (0.037) 80.0 (1.2) Ν/Α 18.4 (1.8) 0.825 (0.002) 97.2 (0.8) 
griseofulvin 0.628 (0.059) 84.1 (3.6) 0.565 (0.045) 41.7 (2.4) 1.036 (0.058) 95.5 (3.3) 
phenytoin 0.364 (0.039) 59.7 (3.3) 0.592 (0.103) 48.0 (2.4) 0.617 (0.155) 90.1 (2.4) 
ibuprofen 1.165 (0.073) 95.8 (0.5) 1.111 (0.163) 86.0 (1.0) 1.228 (0.065) 95.9 (0.46) 
danazol 0.330 (0.043) 93.5 (0.9) 1.033 (0.213) 86.7 (1.8) 0.673 (0.036) 100 (0) 
nifedipine 1.642 (0.022) 100 (0) 3.748 (0.134) 82.3 (1.2) 1.354 (0.018) 100 (0) 
indomethacin 0.697 (0.095) 90.4 (1.7) 2.344 (0.760) 75.6 (3.2) 1.109 (0.240) 95.4 (2.1) 
atorvastatin calcium 0.198 (0.043) 41.6 (11.5) 1.122 (0.211) 23.2 (6.6) 0.207 (0.087) 82.1 (4.3) 
MK-C1 0.404 (0.036) 88.5 (14.1) 1.212 (0.513) 90.4 (1.0) 0.365 (0.044) 88.5 (1.7) 
felodipine 0.390 (0.005) 88.4 (0.8) 1.699 (0.406) 87.9 (2.7) 0.584 (0.166) 98.9 (2.0) 
itraconazole 0.335(0.020) 78.6 (2.8) 0.236 (0.044) 100 (0) N/A 32.4 (2.5) 
MK-C4 0 (0)* - 0.703 (0.066) 93.0 (2.8) 0 (0)* - 
*partition was insignificant; partition rate constants were considered zero 867 
N/A: the first-order model did not fit to the partition data868 
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Figure captions 869 
Figure 1: a. Nifedipine partition profiles to fat using setup I (dialysis membrane) and different 870 
fat percentages. Dashed lines denote the fittings to the first-order model. b. Bars denote the 871 
first-order partition rates of nifedipine partition to fat in setup I. 872 
Figure 2: Danazol partition profiles to fat using the setup II under different agitation 873 
conditions. 874 
Figure 3: Drug partition profiles to fat using a. setup I, b. setup II and c. setup III. The marker 875 
colour is representative of drug lipophilicity (log D pH 5); white colour for the five more 876 
hydrophilic drugs, blue colour for the five moderately lipophilic and red for the five most 877 
lipophilic. Dashed lines denote the fittings to the first-order model.  878 
Figure 4: Calculated first-order rates of drug partition studies. Stars denote statistical 879 
differences among setups (two-way ANOVA, Bonferroni post-hoc test, * < 0.05, ** < 0.01, 880 
*** < 0.001). Different letters denote statistically significant differences (p < 0.05) among 881 
partition rates within the same setup. 882 
Figure 5: Drug partition rates to fat in the absence of SLS or RN lipase vs log D pH 5, MW, and 883 
% of un-ionised drug in the working pH. 884 
Figure 6: Standardised coefficients corresponding to the variables (and their interactions) 885 
studied. Green colours denote coefficients of VIP > 1. 886 
Figure 7: Drug partition profiles to fat using the setup III in the presence of a. SLS or b. lipase. 887 
The marker colour is representative of drug lipophilicity (log D pH 5); white colour for the five 888 
more hydrophilic drugs, blue colour for the five moderately lipophilic and red for the five most 889 
lipophilic.  Dashed lines denote the fittings to the first-order model. 890 
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Figure 8: Drug partition rates to fat a. in the presence of SLS or b. RN lipase, vs log D pH 5, 891 
MW and % un-ionised drug at pH 5. 892 
Figure 9: Standardised coefficients corresponding to the variables (and their interactions) 893 
studied. Green colours denote coefficients of VIP > 1. 894 
Figure 10: Standardised coefficients corresponding to the variables (and their interactions) 895 
studied. Green colours denote coefficients of VIP > 1. 896 
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